![]() Xyrem® was designated as an orphan medicinal product on February 3, 2003. by Jazz Pharmaceuticals and has been available in the U.S. In Europe, the approval of Xyrem® for the treatment of cataplexy in patients with narcolepsy provides a welcome addition to the pharmacological armamentarium."ġ. UCB acquired the licence to distribute Xyrem® in Europe from Orphan Medical recently acquired by Jazz Pharmaceuticals). Thomas Hospital, London, UK said "Patients and physicians in the EU should be encouraged by the body of clinical research supporting Xyrem®. Ĭommenting on the marketing approval Adrian Williams MD of Sleep Centre, St. It involves a sudden reversible loss of muscle tone, usually triggered by emotional stimuli such as laughter, excitement, surprise and anger, with contributing factors including physical fatigue, stress or sleepiness. Cataplexy is a typical symptom of narcolepsy and is present in 65-70% of patients with narcolepsy. ![]() ![]() Narcolepsy is a debilitating, life-long neurological disorder that is characterised by excessive daytime sleepiness and sleep attacks. We are delighted to serve European physicians and sleep centres with a product that can help fulfil the unmet medical need in patients with this serious sleep disorder." said Emmanuel Caeymaex, Vice-President, Marketing CNS, UCB. "Xyrem® provides physicians and patients in Europe with the first and only EMEA approved medication for the treatment of cataplexy in patients with narcolepsy. Launch in this first major European market follows the recent European Commission (EC) marketing approval of Xyrem® in this orphan indication, with pan-European commercialisation expected over 2006. Cimzia® - Axial spondyloarthritis (axSpA)īrussels, Belgium - December 8, 2005: UCB announced today that Xyrem® (sodium oxybate) oral solution is now available in Germany for the treatment of cataplexy in adult patients with narcolepsy.Registration and Results Reporting on Public Registries.Plain Language Summaries of research results.Access to Patient-Level Clinical Study Data.Plain language summaries of study results.Hydrocodone bitartrate extended release (HC-ER).Hydrocodone Bitartrate controlled release (HC-CR).Ferrous(II) glycine sulphate complex (Ferro Sanol®).Clinical studies at UCB: How are medicines made and tested?.Disclosure of payments to Healthcare Professionals.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |